Commission Implementing Regulation (EU) 2020/1685 of 12 November 2020 amending Regulation (EU) No 37/2010 to classify the substance bupivacaine as regards its maximum residue limit
Proposed act with possible EEA relevance
Act under scrutiny by EEA EFTA
Draft Joint Committee Decision (JCD) under consideration
Entry into force of Joint Committee Decision (JCD) pending
Incorporated into the EEA Agreement and in force
Incorporated into the EEA Agreement but no longer in force
Legal status
EU legal act incorporated into the EEA Agreement by a Joint Committee Decision (JCD) Area (EEA Agreement)
II Technical Regulations, Standards, Testing and Certification
II.XIII Medicinal Products
Joint committee decision (JCD)
106/2021 In force in the EEA
Yes Legal documents
Commission Implementing Regulation (EU) 2020/1685 of 12 November 2020 amending Regulation (EU) No 37/2010 to classify the substance bupivacaine as regards its maximum residue limit
Framkvæmdarreglugerð framkvæmdastjórnarinnar (ESB) 2020/1685 frá 12. nóvember 2020 um breytingu á reglugerð (ESB) nr. 37/2010 til að flokka efnið búpívakaín með tilliti til hámarksgildis leifa
Durchführungsverordnung (EU) 2020/1685 der Kommission vom 12. November 2020 zur Änderung der Verordnung (EU) Nr. 37/2010 in Bezug auf die Einstufung des Stoffs Bupivacain hinsichtlich der Rückstandshöchstmenge
History
20.03.2021
Adopted JCD confirmed entry into force date
20.03.2021
Compliance date in the EEA
19.03.2021
Adoption of Joint Commitee Decision (JCD) incorporating the act into the EEA Agreement
10.02.2021
Draft Joint Commitee Decision (JCD) incorporating the act into the EEA Agreement sent to Commission
12.11.2020
Adoption date in the EU
03.12.2020
Compliance date in the EU
Disclaimer: EEA-Lex is provided for information purposes only. The information is not guaranteed or promised to be current or complete and is not intended to replace any applicable legal sources.